Home » Topics » BioWorld

BioWorld
RSS

BIOTECH SELL-OFF: BAD, BUT NOT TERRIBLE

April 16, 1992

IMMUNOGEN STARTS EUROPEAN TRIALS

April 16, 1992

IMMURAID GETS ORPHAN DESIGNATION

April 16, 1992

SEPRACOR PATENT COVERS PROZAC ISOMER

April 16, 1992

FDA DEMANDS NEW TRIAL FOR CENTOXIN

April 16, 1992

BETA-AMYLOID PROTEIN LINKED TO BRAIN DAMAGE

April 16, 1992

ELAN BOOSTED AGAIN BY ANNOUNCEMENTS

April 16, 1992

NEW SUCCESS WITH MYOBLAST GENE THERAPY

April 16, 1992

GENE THERAPY FOR BRAIN DISEASE

April 16, 1992

COR GRANT TO STUDY ANTI-THROMBOTIC

April 15, 1992

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.